GlassScriptPhysician profile
Azadeh E Poursaid
NPI 1104321744
$13,664.23
in general payments reported to CMS, 2019-2025
13 companies · $87.57 in 2025
The $87.57 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $325 · 2023: $12K · 2024: $1,067 · 2025: $87.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $12K · Food and Beverage: $848 · Travel and Lodging: $304 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $12,178.99 |
| Food and Beverage | $847.71 |
| Travel and Lodging | $303.79 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $12,774.69 | 2023-2024 | Davinci Xi, Da Vinci Surgical System |
| Medical Device Business Services, INC. | $325.00 | 2022 | |
| Astellas Pharma US INC | $245.59 | 2023-2024 | Veozah |
| Hologic Sales and Service, LLC | $101.51 | 2023-2025 | Acessa Provu System |
| Biogen, INC. | $53.36 | 2024-2025 | Zurzuvae |
| Exeltis, USA INC. | $47.77 | 2023-2024 | Slynd |
| Organon LLC | $23.92 | 2023-2024 | Nexplanon |
| Shield Therapeutics INC | $20.02 | 2025 | |
| Evofem Biosciences, INC. | $16.83 | 2023 | Phexxi |
| Becton, Dickinson and Company | $16.40 | 2024 | Bd Onclarity |
| Coopersurgical, INC. | $14.65 | 2024 | Paragard T 380a |
| Abbvie INC. | $13.28 | 2023 | |
| Meditrina | $11.21 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Azadeh Poursaid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.